Given the poor potency, solubility, and pharmacokinetic profiles of known nSMase2 inhibitors [8,23,24,25,26], D-DPTIP represents a significant improvement in the field with translational potential for the treatment of AD. Here, SMPD3 is linked to Alzheimer disease.